Zacks Investment Research upgraded shares of EDAP TMS SA (NASDAQ:EDAP) from a hold rating to a buy rating in a research note released on Tuesday morning. Zacks Investment Research currently has $3.25 target price on the stock.
According to Zacks, “EDAP TMS S.A. develops, produces, markets and distributes minimally invasive medical devices, primarily for the treatment of urological diseases. They currently produce and market devices for treatment of benign prostate hyperplasia and urinary tract stones. They are also developing a third range of products for minimally invasive destruction of certain types of tumors. “
Other research analysts have also issued reports about the stock. HC Wainwright reiterated a buy rating on shares of EDAP TMS SA in a report on Tuesday, August 30th. TheStreet upgraded shares of EDAP TMS SA from a sell rating to a hold rating in a report on Tuesday, September 27th.
EDAP TMS SA (NASDAQ:EDAP) opened at 2.8499 on Tuesday. The stock has a market capitalization of $81.87 million, a P/E ratio of 17.3774 and a beta of 1.12. EDAP TMS SA has a 1-year low of $2.43 and a 1-year high of $6.57. The stock has a 50 day moving average of $2.91 and a 200 day moving average of $3.26.
EDAP TMS SA (NASDAQ:EDAP) last announced its quarterly earnings data on Thursday, August 25th. The company reported $0.09 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.03) by $0.12. EDAP TMS SA had a net margin of 11.53% and a return on equity of 58.61%. On average, analysts expect that EDAP TMS SA will post $0.16 earnings per share for the current year.
An institutional investor recently bought a new position in EDAP TMS SA stock. Perkins Capital Management Inc. purchased a new stake in shares of EDAP TMS SA (NASDAQ:EDAP) during the second quarter, according to its most recent filing with the SEC. The fund purchased 118,000 shares of the company’s stock, valued at approximately $391,000. Perkins Capital Management Inc. owned 0.46% of EDAP TMS SA as of its most recent filing with the SEC. 12.11% of the stock is owned by hedge funds and other institutional investors.
EDAP TMS SA Company Profile
EDAP TMS SA (EDAP) is a holding company engaged in developing and marketing the Ablatherm and Focal One devices. The Company operates two divisions: High Intensity Focused Ultrasound (HIFU) and Urology Devices and Services (UDS) (including lithotripsy activities). The Company is developing HIFU technology for the treatment of certain other types of tumors.